title: Modulation of autoimmunity by treatment of an infectious disease.
abstract: Chagas' heart disease (CHD), caused by the parasite Trypanosoma cruzi, is the most common form of myocarditis in Central America and South America. Some humans and experimental animals develop both humoral and cell-mediated cardiac-specific autoimmunity during infection. Benznidazole, a trypanocidal drug, is effective at reducing parasite load and decreasing the severity of myocarditis in acutely infected patients. We hypothesized that the magnitude of autoimmunity that develops following T. cruzi infection is directly proportional to the amount of damage caused by the parasite. To test this hypothesis, we used benznidazole to reduce the number of parasites in an experimental model of CHD and determined whether this treatment altered the autoimmune response. Infection of A/J mice with the Brazil strain of T. cruzi leads to the development of severe inflammation, fibrosis, necrosis, and parasitosis in the heart accompanied by vigorous cardiac myosin-specific delayed-type hypersensitivity (DTH) and antibody production at 21 days postinfection. Mice succumbed to infection within a month if left untreated. Treatment of infected mice with benznidazole eliminated mortality and decreased disease severity. Treatment also reduced cardiac myosin-specific DTH and antibody production. Reinfection of treated mice with a heart-derived, virulent strain of T. cruzi or immunization with myosin led to the redevelopment of myosin-specific autoimmune responses and inflammation. These results provide a direct link between the levels of T. cruzi and the presence of autoimmunity and suggest that elimination of the parasite may result in the reduction or elimination of autoimmunity in the chronic phase of infection.
authors.affiliation: Department of Microbiology-Immunology and Pathology, Northwestern University, 303 E. Chicago Avenue, Chicago, IL 60611, USA.
authors.forename: Kenneth V
authors.initials: KV
authors.lastname: Hyland
authors.forename: Juan S
authors.initials: JS
authors.lastname: Leon
authors.forename: Melvin D
authors.initials: MD
authors.lastname: Daniels
authors.forename: Nick
authors.initials: N
authors.lastname: Giafis
authors.forename: LaKitta M
authors.initials: LM
authors.lastname: Woods
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Bahk
authors.forename: Kegiang
authors.initials: K
authors.lastname: Wang
authors.forename: David M
authors.initials: DM
authors.lastname: Engman
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology / Q000503:physiopathology; D015551:Autoimmunity / Q000187:drug effects*; D002598:Chagas Cardiomyopathy / Q000188:drug therapy* / Q000276:immunology* / Q000469:parasitology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D009205:Myocarditis / Q000188:drug therapy / Q000276:immunology / Q000469:parasitology; D009218:Myosins / Q000276:immunology; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014349:Trypanosoma cruzi / Q000276:immunology / Q000472:pathogenicity*
chemical_list: D007166:Immunosuppressive Agents; D009593:Nitroimidazoles; D009218:Myosins; C009999:benzonidazole